` ARYX (ARYx Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread
Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

ARYX
vs
S&P 500

Over the past 12 months, ARYX has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +12% growth.

Back to ARYX Analysis

Stocks Performance
ARYX vs S&P 500

Loading
ARYX
S&P 500
Add Stock
www.alphaspread.com
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ARYX vs S&P 500

Performance Gap Between ARYX and GSPC
HIDDEN
Show

Performance By Year
ARYX vs S&P 500

Loading
ARYX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
ARYx Therapeutics Inc vs Peers

S&P 500
ARYX
JEF
JNJ
4312
Add Stock
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

ARYx Therapeutics Inc
Glance View

Market Cap
33.5 USD
Industry
Pharmaceuticals

ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. The company is headquartered in Fremont, California and currently employs 56 full-time employees. The company went IPO on 2007-11-08. The firm is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. The company is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.

ARYX Intrinsic Value
Not Available
What is Intrinsic Value?
Back to Top
ALPHA SPREAD
Follow us
Join more than 317,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.